Related Experiment Video
Updated: Dec 29, 2025
06:18
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
3.5K
Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
1Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, Milwaukee, WI, 53226, USA.
Current Treatment Options in Oncology
|February 7, 2020
Summary
Chimeric antigen receptor (CAR) T-cell therapy offers a promising treatment for relapsed or refractory acute lymphoblastic leukemia (ALL). Ongoing research aims to enhance CAR-T cell persistence and overcome resistance for improved patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Relapsed or refractory (RR) acute lymphoblastic leukemia (ALL) historically had limited curative options beyond allogeneic hematopoietic stem cell transplantation (HSCT).
- Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in treating hematologic malignancies.
Purpose of the Study:
- To review the current landscape of CAR T-cell therapy in pediatric RR ALL.
- To discuss challenges and future directions for CAR T-cell therapy development.
Main Methods:
- Review of clinical trials and approved CAR T-cell products.
- Analysis of mechanisms contributing to suboptimal responses and resistance.
Main Results:
- Tisagenlecleucel (anti-CD19 CAR-T) is an approved therapy for pediatric RR ALL.
- CAR T-cell therapy has shown durable responses in some patients, but challenges like lack of persistence and antigen downregulation persist.
Conclusions:
- Despite challenges, CAR T-cell therapy has transformed treatment for pediatric RR ALL.
- Future CAR T-cell constructs are being developed to enhance persistence, overcome resistance, and improve safety and efficacy.
